It’s important for investors in drug companies to keep up with the latest clinical trial news, but policy changes in Washington can affect companies’ bottom lines just as much. Last week the House passed a bill reauthorizing the Prescription Drug User Fee Act (PDUFA); let’s take a look at how it will affect drugmakers.
